---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-23T15:00:01.378902'
end_time: '2026-10-23T15:15:23.191725'
duration_seconds: 921.81
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Melanoma and Neural System Tumor Syndrome
  mondo_id: MONDO:0007967
  category: Mendelian
  causal_genes: CDKN2A
  omim_id: OMIM:155755
  synonyms: melanoma-astrocytoma syndrome
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderAuthError
  status_code: 403
  remedy: the API key is missing, invalid, or lacks access to this endpoint
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 39
reference_validation:
  total_references: 39
  verified: 39
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 5
  quotes_valid: 5
  relevance_assessed: 39
  on_topic: 22
  validator_version: 0.3.0
term_validation:
  total_terms: 25
  verified: 21
  not_found: 0
  obsolete: 2
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 18
  labels_matching: 9
  labels_mismatched: 3
  mislabelled_terms:
  - term_id: MONDO:0007967
    reported_labels:
    - MONDO
    ontology_label: melanoma and neural system tumor syndrome
  - term_id: HP:0012056
    reported_labels:
    - Cutaneous melanoma
    - Earlier onset; carriers
    ontology_label: Cutaneous melanoma
  - term_id: GO:0007050
    reported_labels:
    - cell cycle arrest
    ontology_label: GO_0007050
  labels_variant: 6
  obsolete_terms:
  - term_id: HP:0100843
    ontology_label: obsolete Glioblastoma
    replaced_by: HP:0012174
  - term_id: GO:0007050
    ontology_label: GO_0007050
    replaced_by: GO:0051726
  unresolvable_prefixes:
  - HGF
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Melanoma_And_Neural_System_Tumor_Syndrome-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Melanoma_And_Neural_System_Tumor_Syndrome-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Melanoma and Neural System Tumor Syndrome
- **MONDO ID:** MONDO:0007967 (if available)
- **Causal gene(s):** CDKN2A
- **OMIM:** OMIM:155755
- **Synonyms:** melanoma-astrocytoma syndrome
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Melanoma and Neural System Tumor Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Melanoma and Neural System Tumor Syndrome (Melanoma–Astrocytoma Syndrome): A Comprehensive Disease Report

**MONDO:** MONDO:0007967 · **OMIM:** 155755 · **Causal gene:** *CDKN2A* (9p21.3) · **Inheritance:** Autosomal dominant · **Category:** Mendelian cancer-predisposition syndrome

---

## Summary

**Melanoma and Neural System Tumor Syndrome**—more commonly called **melanoma–astrocytoma syndrome (MAS)**—is a rare, autosomal-dominant hereditary cancer-predisposition syndrome caused by **germline loss-of-function variants in the *CDKN2A* tumor-suppressor gene at chromosome 9p21.3**. The defining clinical feature is the co-occurrence, within families and often within individuals, of **cutaneous melanoma** and **tumors of the neural/nervous system** (most characteristically astrocytoma and other gliomas, but also glioblastoma, schwannoma, and meningioma). The *CDKN2A* locus is unusual in that it encodes **two distinct tumor-suppressor proteins from overlapping reading frames**: **p16INK4A**, which restrains the CDK4/6–Rb cell-cycle checkpoint, and **p14ARF** (p19ARF in mouse), which stabilizes p53 by inhibiting MDM2. This dual-protein architecture explains the dual-tumor phenotype: loss of p16INK4A predisposes principally to melanoma, whereas loss of **p14ARF (encoded by the ARF-specific exon 1β)** is the critical lesion underlying the neural-system tumor component.

The mechanistic core of the disease is a **two-hit tumor-suppressor model**: affected individuals inherit one inactivated *CDKN2A* allele in the germline, and tumors arise when the remaining wild-type allele is somatically lost (commonly by homozygous 9p21 deletion). In melanocytes, loss of p16INK4A allows cells carrying oncogenic drivers (e.g., BRAF-V600E) to **escape oncogene-induced senescence**, enabling progression from nevus to melanoma. In glial and neural-crest-derived cells, loss of p14ARF **disables the ARF–MDM2–p53 axis**, removing a key apoptotic/senescence barrier and cooperating with additional somatic drivers (e.g., BRAF alterations) to produce astrocytomas. Somatic **homozygous *CDKN2A/B* deletion** is now a formally recognized molecular marker of grade 4 in IDH-mutant astrocytoma under the 2021 WHO CNS classification.

Penetrance is **incomplete and age-dependent**, with lifetime melanoma risk estimates of 52–84% for high-penetrance carriers, and is strongly modulated by **environmental factors (UV radiation for melanoma; tobacco smoking for pancreatic cancer)** and **modifier genes (notably MC1R)**. *CDKN2A* carriers also carry a substantially elevated risk of **pancreatic ductal adenocarcinoma (PDAC)**. Clinical management is not syndrome-specific but combines **germline genetic testing and counseling, UV/smoking risk reduction, dermatologic surveillance, and pancreatic imaging surveillance (MRI/MRCP ± EUS)**, with tumors treated per standard melanoma, glioma, and pancreatic-cancer protocols. The *CDKN2A*–CDK4/6 axis is a rational precision-oncology target (CDK4/6 inhibitors).

---

## Disease Information (Section 1)

**Overview.** Melanoma–astrocytoma syndrome is an inherited syndrome in which individuals have an increased risk of developing both **cutaneous malignant melanoma** and **nervous-system tumors**, classically astrocytomas. It represents a phenotypic subset of the broader *CDKN2A*-related familial melanoma / familial atypical multiple mole melanoma (FAMMM) spectrum, distinguished by the presence of neural-system tumors. Because melanocytes and glial/Schwann cells share a **common neuroectodermal/neural-crest embryologic origin**, a shared genetic lesion predisposing to both is biologically coherent ([PMID: 36980355](https://pubmed.ncbi.nlm.nih.gov/36980355/)).

**Key identifiers:**

| Resource | Identifier |
|---|---|
| MONDO | MONDO:0007967 |
| OMIM | 155755 |
| Causal gene | *CDKN2A* (HGNC:1787), 9p21.3 |
| Synonyms | Melanoma–astrocytoma syndrome; melanoma and neural system tumor syndrome; CMM+NST (cutaneous malignant melanoma + neural system tumor) |

**Synonyms / alternative names:** melanoma–astrocytoma syndrome; melanoma–neural system tumour syndrome; CMM+NST syndrome.

**Information source type.** The evidence base derives overwhelmingly from **aggregated disease-level resources**—individual case reports, melanoma-prone family kindreds, familial-melanoma registries (e.g., the Dutch national familial melanoma database), and biobank-scale cohorts (UK Biobank, Geisinger MyCode)—rather than from single-patient EHR extraction.

---

## Etiology (Section 2)

**Primary cause (genetic).** The disease is caused by **germline inactivating variants in *CDKN2A***. Multiple kindreds demonstrate germline 9p21 deletions or point mutations spanning *CDKN2A*. Bahuau et al. 1998 found a lesion disrupting p16 and p19ARF but sparing p15 that segregated with melanoma–astrocytoma syndrome (MIM 155755) ([PMID: 9622062](https://pubmed.ncbi.nlm.nih.gov/9622062/)). Critically, Randerson-Moor et al. 2001 reported a family with a **germline deletion of the p14ARF-specific exon 1β only** (not affecting p16 or CDKN2B coding regions), implicating **p14ARF loss as the critical driver of the neural-system tumor component** ([PMID: 11136714](https://pubmed.ncbi.nlm.nih.gov/11136714/)). Exon 1β / ARF-specific lesions predisposing to CNS tumors are corroborated by Wong 2022 ([PMID: 35904890](https://pubmed.ncbi.nlm.nih.gov/35904890/)) and Hewitt 2002 ([PMID: 12019208](https://pubmed.ncbi.nlm.nih.gov/12019208/)).

**Genetic risk factors.**
- *CDKN2A* germline loss-of-function variants (causal).
- **CDK4** germline mutations cause a smaller fraction of hereditary melanoma (functionally equivalent downstream lesion) ([PMID: 10630172](https://pubmed.ncbi.nlm.nih.gov/10630172/)).
- **MC1R** (melanocortin-1 receptor) variants act as low-penetrance **modifiers** that increase melanoma risk and cosegregate with deleterious p16 alleles ([PMID: 16462187](https://pubmed.ncbi.nlm.nih.gov/16462187/)).

**Environmental risk factors.**
- **Ultraviolet (UV) radiation** is the dominant environmental driver of the melanoma component. "The penetrance of these melanoma-predisposing genes is largely influenced by ultraviolet exposure across geographic latitude" ([PMID: 16462187](https://pubmed.ncbi.nlm.nih.gov/16462187/)).
- **Tobacco smoking** dramatically amplifies pancreatic-cancer risk in carriers (HR 25.8 for ever-smokers vs non-carriers; p = 2.1 × 10⁻¹³) ([PMID: 21150883](https://pubmed.ncbi.nlm.nih.gov/21150883/)).
- **Age, sex, and family history** act as standard modifiers; penetrance rises steeply with age.

**Protective factors.**
- **Environmental:** UV avoidance / sun protection and smoking cessation reduce melanoma and pancreatic risk respectively. Genetic counseling measurably reduces objectively measured UV exposure in carriers ([PMID: 31371819](https://pubmed.ncbi.nlm.nih.gov/31371819/)).
- **Genetic protective factors:** No well-established protective alleles are documented specific to this syndrome; absence of high-risk MC1R variants and a darker constitutive pigmentation background are relatively protective against the UV-driven melanoma component.

**Gene–environment interactions.** Two strong G×E interactions are documented: (1) **UV × CDKN2A** for melanoma—UV induces melanoma-like cell-cycle/DNA-damage transcriptomic changes even in phenotypically normal *CDKN2A*-heterozygous fibroblasts ([PMID: 23371019](https://pubmed.ncbi.nlm.nih.gov/23371019/)); and (2) **smoking × CDKN2A** for pancreatic cancer (HR 25.8) ([PMID: 21150883](https://pubmed.ncbi.nlm.nih.gov/21150883/)).

---

## Phenotypes (Section 3)

The syndrome is defined by a **dual tumor spectrum**. In an unbiased UK Biobank cohort of MAS cases, the tumor spectrum was: brain neoplasms 33% (glioblastoma, gliosarcoma, astrocytoma), schwannomas 25%, cutaneous melanoma 17%, and head/neck squamous cell carcinoma 17% ([PMID: 37585199](https://pubmed.ncbi.nlm.nih.gov/37585199/)).

| Phenotype | Type | Frequency | Onset / course | Suggested HPO term |
|---|---|---|---|---|
| Cutaneous melanoma | Neoplasm (physical manifestation) | ~17% (biobank); lifetime risk 52–84% in high-penetrance carriers | Younger age at onset than sporadic; often multiple primaries | HP:0012056 (Cutaneous melanoma) |
| Multiple primary melanomas | Neoplasm | Up to ~10% of melanoma series | Earlier onset; carriers | HP:0012056 |
| Dysplastic/atypical nevi | Physical manifestation (precursor) | Frequent in kindreds | Childhood–adult | HP:0003764 (Nevus) |
| Astrocytoma / diffuse glioma | Neoplasm (nervous system) | Major neural component | Variable; pediatric or adult | HP:0009592 (Astrocytoma) |
| Glioblastoma / gliosarcoma | Neoplasm (nervous system) | Within the 33% brain-tumor group | Adult; aggressive | HP:0100843 (Glioblastoma multiforme) |
| Schwannoma / peripheral nerve sheath tumor | Neoplasm (nervous system) | ~25% | Variable | HP:0100008 (Schwannoma) |
| Meningioma | Neoplasm (nervous system) | Reported | Adult | HP:0002858 (Meningioma) |
| Pancreatic ductal adenocarcinoma | Neoplasm (digestive) | ~8.9% cumulative in surveilled carriers; up to 58% penetrance by age 80 | Adult/late | HP:0002894 (Pancreatic adenocarcinoma) |
| NF1-like features | Physical manifestation | Reported subset | — | — |

**Severity and progression.** Phenotype is **variable** with incomplete penetrance and variable expressivity. Melanomas in carriers tend to be thinner (lower Breslow thickness), superficial-spreading, and in-situ predominant, consistent with younger onset and surveillance detection ([PMID: 30218143](https://pubmed.ncbi.nlm.nih.gov/30218143/)). Neural tumors range from low-grade astrocytoma to lethal glioblastoma.

**Quality-of-life impact.** No syndrome-specific QoL instruments (EQ-5D/SF-36) data were identified. QoL impact derives from the component tumors—neurological deficit, seizures, and cognitive effects from brain tumors; surgical morbidity; and the psychological burden of lifelong cancer surveillance.

---

## Genetic / Molecular Information (Section 4)

**Causal gene.** *CDKN2A* (cyclin-dependent kinase inhibitor 2A; HGNC:1787; OMIM 600160), located at **9p21.3**. The *CDKN2A* locus uses alternative first exons and overlapping reading frames to encode two unrelated proteins:
- **p16INK4A** (exon 1α) — CDK4/6 inhibitor acting in the Rb pathway.
- **p14ARF** (exon 1β; p19ARF in mouse) — MDM2 inhibitor acting in the p53 pathway.

The neighboring **CDKN2B** gene (encoding p15INK4B) is frequently co-deleted in large 9p21 deletions.

**Pathogenic variant classes.**
- **Large germline 9p21 deletions** spanning p16/p14ARF (± CDKN2B) ([PMID: 9622062](https://pubmed.ncbi.nlm.nih.gov/9622062/)).
- **ARF-specific (exon 1β) deletions / point mutations**—e.g., germline exon 1β deletion ([PMID: 11136714](https://pubmed.ncbi.nlm.nih.gov/11136714/)); exon 1β deletion with melanoma + neural tumors ([PMID: 35904890](https://pubmed.ncbi.nlm.nih.gov/35904890/)); an ARF splice mutation causing ARF haploinsufficiency ([PMID: 12019208](https://pubmed.ncbi.nlm.nih.gov/12019208/)); p14ARF exon 1β missense G16D in a CMM+NST family ([PMID: 15937071](https://pubmed.ncbi.nlm.nih.gov/15937071/)).
- **Founder frameshift variants** — **p16-Leiden (c.225_243del, p.Ala76fs)**, the major Dutch founder allele ([PMID: 32482799](https://pubmed.ncbi.nlm.nih.gov/32482799/), [PMID: 22636603](https://pubmed.ncbi.nlm.nih.gov/22636603/)); and c.19_23dup (p.Ser8fs).
- **Missense variants** — e.g., c.442G>A (p.Ala148Thr), c.249C>A (p.His83Gln) ([PMID: 32221274](https://pubmed.ncbi.nlm.nih.gov/32221274/)).

Variants are classified **pathogenic/likely pathogenic** per ACMG/AMP for the recurrent founder and truncating alleles; some missense changes (e.g., p.Ala148Thr) are of debated/variable clinical significance.

**Somatic vs germline.** The syndrome is **germline-driven** (one inherited hit), with tumors completing inactivation via **somatic loss of the second allele**. In MAS astrocytomas, tumors showed **homozygous deletion of *CDKN2A/B* due to somatic loss of the other copy of chromosome 9p**, plus additional somatic drivers (BRAF) ([PMID: 28699883](https://pubmed.ncbi.nlm.nih.gov/28699883/)).

**Functional consequence.** **Loss of function** of both tumor-suppressor proteins (p16INK4A and p14ARF), producing failure of cell-cycle arrest and of p53-mediated senescence/apoptosis.

**Modifier genes.** **MC1R** (melanoma risk modifier) ([PMID: 16462187](https://pubmed.ncbi.nlm.nih.gov/16462187/)); **MITF** (e.g., p.Glu318Lys, associated with nodular melanoma) ([PMID: 32221274](https://pubmed.ncbi.nlm.nih.gov/32221274/)).

**Epigenetic information.** While MAS is primarily driven by genetic *CDKN2A* loss, the associated IDH-mutant gliomas display extensive **DNA/histone methylation reprogramming (G-CIMP)**; DNA methylation profiling is used for CNS tumor classification, integrated with homozygous *CDKN2A/B* deletion status ([PMID: 42630077](https://pubmed.ncbi.nlm.nih.gov/42630077/)).

**Chromosomal abnormalities.** Large-scale **9p21 germline deletions** are the hallmark structural lesion; tumors frequently show **9p21 homozygous deletion** and, in IDH-wildtype glioblastoma, chromosome +7/−10 ([PMID: 42158566](https://pubmed.ncbi.nlm.nih.gov/42158566/)).

---

## Environmental Information (Section 5)

- **Environmental factors:** **UV radiation** (solar and artificial) is the principal environmental carcinogen driving the melanoma component; its effect is strongly latitude-dependent and interacts with *CDKN2A* and MC1R genotype ([PMID: 16462187](https://pubmed.ncbi.nlm.nih.gov/16462187/)). UV induces melanoma-like transcriptomic dysregulation in *CDKN2A*-heterozygous cells ([PMID: 23371019](https://pubmed.ncbi.nlm.nih.gov/23371019/)).
- **Lifestyle factors:** **Tobacco smoking** is a powerful modifier of pancreatic-cancer risk in carriers (HR 25.8) ([PMID: 21150883](https://pubmed.ncbi.nlm.nih.gov/21150883/)). Sun-seeking behavior and tanning-bed use increase melanoma risk.
- **Infectious agents:** None. This is a Mendelian cancer-predisposition syndrome with no infectious etiology.

---

## Mechanism / Pathophysiology (Section 6)

### Ordered causal chain

```
1. Germline inactivating CDKN2A variant (9p21.3) is inherited
       → every somatic cell carries one defective allele ("first hit")
                 │
2. A somatic "second hit" (commonly homozygous 9p21 deletion) inactivates the
   remaining wild-type CDKN2A allele in a target cell
                 │
      ┌──────────┴───────────────────────────────┐
      │ (branch A: p16INK4A)        (branch B: p14ARF) │
      ▼                                            ▼
3A. Loss of p16INK4A → CDK4/6 no          3B. Loss of p14ARF → MDM2 is no
   longer inhibited → hyper-                longer sequestered → MDM2
   phosphorylation of Rb →                  degrades p53 → loss of p53-
   release of E2F → unchecked G1→S          dependent senescence/apoptosis
   cell-cycle progression
      │                                            │
4A. In melanocytes carrying an            4B. In glial / neural-crest-derived
   oncogenic driver (e.g., BRAF-            cells, p53-axis failure cooperates
   V600E), loss of p16 removes the          with additional somatic drivers
   oncogene-induced senescence (OIS)        (e.g., BRAF alterations) to permit
   barrier → escape from senescence         proliferation and malignant
      │                                      transformation
      ▼                                            ▼
5A. Nevus → dysplastic nevus →            5B. Astrocytoma / glioma /
   cutaneous MELANOMA                       glioblastoma; schwannoma;
                                            meningioma (NEURAL SYSTEM TUMORS)
                 │
6. Additional organ risk: pancreatic ductal adenocarcinoma (p16 loss +
   smoking), with high age-dependent penetrance
```

*(Branches A and B are both engaged when large germline deletions disrupt the whole locus; ARF-specific exon-1β lesions preferentially engage branch B and the neural component. Steps 4A/4B are mechanistically demonstrated in vitro and in mouse; the exact cell-of-origin sequence for the human neural tumors is partly inferred.)*

### Detail

**Molecular pathways.** Two canonical tumor-suppressor pathways converge at the *CDKN2A* locus:
- **p16INK4A → CDK4/6 → Rb → E2F (cell-cycle control).** "The p16INK4a tumor suppressor protein functions as an inhibitor of CDK4 and CDK6, the D-type cyclin-dependent kinases that initiate the phosphorylation of the retinoblastoma tumor suppressor protein, RB" ([PMID: 15460900](https://pubmed.ncbi.nlm.nih.gov/15460900/)). Loss of p16 releases the Rb checkpoint, permitting uncontrolled G1→S transition.
- **p14ARF → MDM2 → p53 (apoptosis/senescence control).** "The role of ARF as a tumor suppressor is closely linked to the p53-MDM2 axis, which is a key process that restrains tumor formation" ([PMID: 29665672](https://pubmed.ncbi.nlm.nih.gov/29665672/)). ARF sequesters MDM2, stabilizing p53; ARF loss leads to MDM2-mediated p53 degradation.
- **MAPK (BRAF) cooperation.** Oncogenic BRAF/RAS signaling provides the proliferative drive that *CDKN2A* loss un-brakes; in glioma, p53-pathway disablement by p14ARF deletion combines with MDM2/MDM4 amplification ([PMID: 21200141](https://pubmed.ncbi.nlm.nih.gov/21200141/)).

**Cellular processes.** The central cellular mechanism is **failure of oncogene-induced senescence (OIS)**. "Malignant melanomas often arise from nevi, which result from initial oncogene-induced hyperproliferation of melanocytes that are maintained in a CDKN2A/p16-mediated senescent state" ([PMID: 27872202](https://pubmed.ncbi.nlm.nih.gov/27872202/)). Removal of the p16 barrier (or CDK6 overexpression) bypasses senescence; removal of the ARF–p53 barrier removes apoptotic backup. Both result in **cell-cycle dysregulation** and escape from two independent proliferation brakes.

**Protein dysfunction.** Both encoded proteins are rendered non-functional (**loss of function**): p16INK4A can no longer bind/inhibit CDK4/6; p14ARF can no longer bind/sequester MDM2.

**Immune / metabolic / tissue-damage mechanisms.** UV-induced DNA damage in melanocytes is the proximal mutagenic insult for the melanoma branch; in the pancreatic branch, tobacco carcinogens plus p16 loss drive adenocarcinoma. These are **genotoxic/oxidative-stress mechanisms** rather than autoimmune or metabolic.

**Suggested ontology terms.**
- GO biological process: GO:0007050 (cell cycle arrest); GO:0090398 (cellular senescence); GO:0006915 (apoptotic process); GO:0072332 (intrinsic apoptotic signaling by p53 class mediator); GO:0000079 (regulation of CDK activity).
- CL cell types: CL:0000148 (melanocyte); CL:0000127 (astrocyte); CL:0002573 (Schwann cell); neural-crest-derived lineages.

---

## Anatomical Structures Affected (Section 7)

**Organ level.**
- **Primary:** skin (UBERON:0002097), brain (UBERON:0000955), peripheral nerves (UBERON:0001021).
- **Secondary:** pancreas (UBERON:0001264); head/neck mucosa (squamous cell carcinoma reported).
- **Body systems:** integumentary, central nervous system, peripheral nervous system, digestive (pancreas).

**Tissue and cell level.**
- **Tissues:** epidermal/melanocytic (skin), glial/neural tissue (brain), peripheral nerve sheath (connective/neural).
- **Cell populations (CL terms):** melanocytes (CL:0000148), astrocytes (CL:0000127), Schwann cells (CL:0002573), pancreatic ductal epithelial cells (CL:0002079). All melanocytes, astrocytes, and Schwann cells share a **neural-crest / neuroectodermal origin**, which underlies the syndrome's combined skin + nervous-system phenotype ([PMID: 36980355](https://pubmed.ncbi.nlm.nih.gov/36980355/)).

**Subcellular level (GO Cellular Component).** Nucleus (GO:0005634) — site of Rb/E2F and p53/MDM2 regulation; nucleolus (GO:0005730) — where ARF resides and senses nucleolar/oncogenic stress; cytoplasm for MDM2 shuttling.

**Localization / lateralization.** Melanomas arise at sun-exposed cutaneous sites; brain tumors are commonly supratentorial but can occur in posterior fossa. Lateralization is tumor-specific and not characteristically unilateral or bilateral at the syndrome level.

---

## Temporal Development (Section 8)

- **Onset.** Variable. Melanoma in *CDKN2A* carriers typically presents at a **younger age than sporadic melanoma**, often with multiple primaries ([PMID: 32221274](https://pubmed.ncbi.nlm.nih.gov/32221274/), [PMID: 30218143](https://pubmed.ncbi.nlm.nih.gov/30218143/)). Neural tumors can present in childhood or adulthood. Pancreatic cancer is adult/late-onset.
- **Progression.** The melanoma branch follows the **nevus → dysplastic nevus → melanoma** sequence. Astrocytomas can progress to higher grade; homozygous *CDKN2A/B* deletion upgrades IDH-mutant astrocytoma to WHO grade 4 ([PMID: 42630077](https://pubmed.ncbi.nlm.nih.gov/42630077/)). Progression rate is variable and tumor-dependent.
- **Disease course.** Lifelong predisposition (chronic, germline) with episodic tumor events; penetrance accumulates with age.
- **Critical periods.** Cumulative UV exposure throughout life is the key modifiable window for the melanoma branch; genetic counseling can intervene behaviorally ([PMID: 31371819](https://pubmed.ncbi.nlm.nih.gov/31371819/)).

---

## Inheritance and Population (Section 9)

**Epidemiology.** MAS is **rare**. Sargen et al. 2023 estimated prevalence ranging from **1 in 170,503 (Geisinger MyCode)** to **1 in 39,149 (UK Biobank; 12 cases / 469,789)** ([PMID: 37585199](https://pubmed.ncbi.nlm.nih.gov/37585199/)).

**Inheritance pattern.** **Autosomal dominant** with incomplete, age-dependent penetrance and variable expressivity. The Dutch national familial melanoma database identified 172 families carrying 15 different pathogenic *CDKN2A* variants in 649 individuals ([PMID: 32482799](https://pubmed.ncbi.nlm.nih.gov/32482799/)).

**Penetrance.** Incomplete and age-dependent. For *CDKN2A* carriers, penetrance by age 80 was estimated at **58% for pancreatic cancer (95% CI 8–86%)** and **39% for melanoma (95% CI 0–80%)** in one unselected pancreatic-cancer-ascertained cohort ([PMID: 21150883](https://pubmed.ncbi.nlm.nih.gov/21150883/)); high-penetrance carriers in familial-melanoma series face lifetime melanoma risk of **52–84%** ([PMID: 38287743](https://pubmed.ncbi.nlm.nih.gov/38287743/)).

**Expressivity.** Variable—some families express predominantly melanoma, others melanoma + neural tumors + pancreatic cancer.

**Founder effects.** **p16-Leiden (c.225_243del, p.Ala76fs)** is the predominant Dutch founder allele ([PMID: 32482799](https://pubmed.ncbi.nlm.nih.gov/32482799/), [PMID: 22636603](https://pubmed.ncbi.nlm.nih.gov/22636603/)).

**Genetic anticipation / germline mosaicism / consanguinity:** no specific evidence; not a repeat-expansion disorder.

**Population demographics.** Documented in multiple populations (Dutch, Italian, UK). Melanoma penetrance is higher in high-UV, low-latitude geographies ([PMID: 16462187](https://pubmed.ncbi.nlm.nih.gov/16462187/)). No strong sex ratio established at the syndrome level.

---

## Diagnostics (Section 10)

**Genetic testing (the cornerstone).** Diagnosis rests on identifying a **germline *CDKN2A* pathogenic variant**, by single-gene testing or multigene hereditary-cancer panels. A *CDKN2A* mutation is identified in **~10–40% of families meeting testing criteria**, and multigene panels increase yield ([PMID: 38287743](https://pubmed.ncbi.nlm.nih.gov/38287743/)). Testing thresholds are incidence-dependent: ≥2 affected first-degree relatives in low-incidence countries, 3–4 affected members in high-incidence countries (USA/Australia) ([PMID: 38287743](https://pubmed.ncbi.nlm.nih.gov/38287743/)). A diagnosis of MAS specifically requires a germline *CDKN2A* pathogenic variant **plus ≥1 neural-system tumor** ([PMID: 37585199](https://pubmed.ncbi.nlm.nih.gov/37585199/)). WES/WGS and gene panels are all applicable; chromosomal microarray / FISH can detect large 9p21 deletions.

**Tumor (somatic) diagnostics.**
- **Homozygous *CDKN2A/B* deletion** on tumor sequencing, FISH, or chromosomal microarray—a molecular criterion for grade-4 IDH-mutant astrocytoma ([PMID: 42630077](https://pubmed.ncbi.nlm.nih.gov/42630077/), [PMID: 28699883](https://pubmed.ncbi.nlm.nih.gov/28699883/)).
- **DNA methylation profiling** for CNS-tumor classification ([PMID: 42630077](https://pubmed.ncbi.nlm.nih.gov/42630077/)).
- **Histopathology / immunohistochemistry:** loss of p16 staining supports tumor diagnosis; **S100B** and dermoscopic/histologic criteria (ABCDE) aid melanoma diagnosis ([PMID: 40581420](https://pubmed.ncbi.nlm.nih.gov/40581420/)).

**Clinical criteria.** Dermatologic examination for atypical/dysplastic nevi; neuroimaging (MRI) for neural tumors. **Differential diagnosis** includes other familial-melanoma genes (CDK4, MITF, BAP1, POT1), neurofibromatosis type 1 (MAS can have NF1-like features), and Li-Fraumeni syndrome.

**Screening.** Cascade genetic testing of relatives; dermatologic surveillance; pancreatic imaging surveillance in carriers (below).

---

## Outcome / Prognosis (Section 11)

**Melanoma.** Carrier melanomas tend to be **thinner and earlier-stage** (more in-situ and superficial-spreading, lower Breslow thickness), consistent with surveillance detection and favorable early-stage prognosis ([PMID: 30218143](https://pubmed.ncbi.nlm.nih.gov/30218143/)). Modern adjuvant therapy improves outcomes: 5-year melanoma-specific survival of **74% with adjuvant therapy vs 60% with observation (adjusted HR 0.58)** in high-risk resected melanoma ([PMID: 42849920](https://pubmed.ncbi.nlm.nih.gov/42849920/)).

**Neural tumors.** Prognosis depends on tumor type/grade—astrocytomas carry variable prognosis; glioblastoma is highly lethal. Homozygous *CDKN2A/B* deletion marks aggressive (grade-4) IDH-mutant astrocytoma ([PMID: 42630077](https://pubmed.ncbi.nlm.nih.gov/42630077/)). High-grade astrocytoma with piloid features (CDKN2A/B loss in 78%) had median overall survival of ~88 months ([PMID: 42747321](https://pubmed.ncbi.nlm.nih.gov/42747321/)).

**Pancreatic cancer.** Historically lethal (sporadic 5-year survival ~8%), but **surveillance improves outcomes**: in 347 *CDKN2A* carriers followed 20 years, PDAC developed in 31 (8.9%), with **83.3% resectable at imaging**, and **5-year survival 32.4% overall / 44.1% after resection** ([PMID: 35658523](https://pubmed.ncbi.nlm.nih.gov/35658523/)). Surveillance reduced PDAC mortality by 12.1% and increased life expectancy by 2.10 years ([PMID: 36785917](https://pubmed.ncbi.nlm.nih.gov/36785917/)).

**Prognostic factors / biomarkers.** Tumor stage/grade, molecular markers (homozygous *CDKN2A/B* deletion, IDH status, ATRX), resectability of pancreatic lesions, Breslow thickness for melanoma.

---

## Treatment (Section 12)

There is **no syndrome-specific therapy**; component tumors are treated per standard oncology protocols, but the *CDKN2A*–CDK4/6 axis is an actionable precision target.

**Melanoma (NCIT: C15262 immunotherapy; C15632 targeted therapy).**
- **Immune checkpoint inhibitors (anti-PD-1)** and **BRAF/MEK inhibitors** substantially improve survival in advanced melanoma ([PMID: 42891779](https://pubmed.ncbi.nlm.nih.gov/42891779/), [PMID: 42907470](https://pubmed.ncbi.nlm.nih.gov/42907470/)).
- **Adjuvant anti-PD-1 / BRAF-MEK** improves 5-year melanoma-specific survival (74% vs 60%, HR 0.58) ([PMID: 42849920](https://pubmed.ncbi.nlm.nih.gov/42849920/)).
- Molecular tumor-board profiling identifies **CDK4/6 pathway amplifications** as actionable targets ([PMID: 42907470](https://pubmed.ncbi.nlm.nih.gov/42907470/)).

**CDK4/6 inhibition (precision target; NCIT: C178229 class).** Because *CDKN2A/p16* loss causes **universal activation of CDK4/6 and Rb pathways**, CDK4/6-specific inhibitors (e.g., **palbociclib**) are a rational targeted strategy in CDKN2A-null tumors ([PMID: 26183925](https://pubmed.ncbi.nlm.nih.gov/26183925/)).

**Neural tumors.** Astrocytomas: maximal safe surgical resection, radiotherapy, and alkylating chemotherapy (temozolomide). For WHO grade-2 IDH-mutant gliomas, **vorasidenib** (mutant-IDH inhibitor) can delay progression in selected patients ([PMID: 42430039](https://pubmed.ncbi.nlm.nih.gov/42430039/)).

**Pancreatic cancer.** Surgical resection when detected early via surveillance; standard systemic chemotherapy; PARP inhibitors for BRCA-associated cases (not *CDKN2A*-specific).

**Pharmacogenomics / personalized medicine.** BRAF-V600 status guides BRAF/MEK inhibitor use; genotype-guided CDK4/6 inhibition is under investigation.

---

## Prevention (Section 13)

- **Primary prevention:** UV risk reduction (sun protection, avoidance of tanning beds) and smoking cessation. Monthly skin self-examination and sun-exposure moderation are long-standing recommendations ([PMID: 10630172](https://pubmed.ncbi.nlm.nih.gov/10630172/)). Genetic counseling with test disclosure produces measurable reductions in objectively measured UV exposure and increases in skin pigmentation one year later ([PMID: 31371819](https://pubmed.ncbi.nlm.nih.gov/31371819/)); priority-of-risk perception predicts improved sun protection ([PMID: 32415830](https://pubmed.ncbi.nlm.nih.gov/32415830/)).
- **Secondary prevention:** Dermatologic surveillance (clinical skin exams 1–2×/year) detects early curable melanoma (e.g., a curable melanoma detected in a 17-year-old during surveillance) ([PMID: 22636603](https://pubmed.ncbi.nlm.nih.gov/22636603/)). **Pancreatic surveillance** with annual MRI/MRCP ± endoscopic ultrasound detects resectable PDAC and is cost-effective (€14,000/QALY) ([PMID: 35658523](https://pubmed.ncbi.nlm.nih.gov/35658523/), [PMID: 36785917](https://pubmed.ncbi.nlm.nih.gov/36785917/)).
- **Tertiary prevention:** Standard tumor-directed therapy and ongoing surveillance for additional primaries.
- **Genetic counseling / cascade testing:** central to risk assessment and family planning; all kindred members (regardless of mutation status) should adhere to sun protection and skin surveillance ([PMID: 30775140](https://pubmed.ncbi.nlm.nih.gov/30775140/)).
- **Immunization / public health / infectious control:** not applicable.

---

## Other Species / Natural Disease (Section 14)

- **Orthologous gene:** mouse *Cdkn2a* (Ink4a/Arf locus), NCBI Gene ID 12578; the mouse ARF protein is **p19ARF** (vs human p14ARF).
- **Natural disease:** No well-characterized naturally occurring melanoma–astrocytoma syndrome in companion animals or wildlife was identified in this investigation; the disease is studied primarily through engineered mouse models (below).
- **Comparative biology:** The Ink4a/Arf tumor-suppressor architecture and both the Rb and p53 pathways are **evolutionarily conserved** between mouse and human, making the mouse a faithful system for the core mechanism ([PMID: 12406321](https://pubmed.ncbi.nlm.nih.gov/12406321/)).
- **Transmission / zoonotic potential:** not applicable (germline genetic disease).

---

## Model Organisms (Section 15)

**Mouse models** recapitulate *CDKN2A*-driven melanoma predisposition via Ink4a/Arf loss cooperating with Ras/MAPK activation and UV:
- "Both the Ink4a/pRb and Arf/p53 pathways are involved in melanoma development in mice" ([PMID: 12406321](https://pubmed.ncbi.nlm.nih.gov/12406321/)); Cdkn2a (Ink4a/Arf) loss cooperates with Ras/MAPK activation to induce melanoma.
- **HGF:p16/Cdkn2a UV-induced melanoma GEMM** used to study metastasis suppressors (Nme1/Nme2) ([PMID: 33024267](https://pubmed.ncbi.nlm.nih.gov/33024267/)).
- **ESC-GEMM platforms** combine Cdkn2a loss with Braf/Pten alleles for rapid melanoma modeling ([PMID: 31744817](https://pubmed.ncbi.nlm.nih.gov/31744817/)).
- **Knockout mice** for CDK inhibitors generated by engineered-nuclease genome editing ([PMID: 30671114](https://pubmed.ncbi.nlm.nih.gov/30671114/)).

**Model types:** knockout, conditional, transgenic, and humanized (HGF) mouse models; melanoma cell lines.
**Phenotype recapitulation:** strong for the melanoma/UV/MAPK axis and both tumor-suppressor pathways.
**Limitations:** the combined melanoma + neural-system tumor syndromic phenotype and ARF-specific exon-1β human lesions are incompletely modeled; human-specific p14ARF vs mouse p19ARF differences exist.
**Resources:** MGI (mouse *Cdkn2a*), IMPC/KOMP, IMSR.

---

## Mechanistic Model / Interpretation

The unifying model is a **dual-tumor-suppressor, two-hit, two-branch** architecture centered on a single genetic locus:

| Feature | p16INK4A branch | p14ARF branch |
|---|---|---|
| Encoded by | *CDKN2A* exon 1α | *CDKN2A* exon 1β |
| Pathway | CDK4/6 → Rb → E2F | MDM2 → p53 |
| Biological brake | Oncogene-induced senescence / G1 arrest | p53-dependent senescence & apoptosis |
| Principal tumor | Cutaneous melanoma | Astrocytoma / neural-system tumors |
| Key environmental modifier | UV radiation | — (intrinsic genotoxic stress) |
| Representative evidence | [PMID: 27872202](https://pubmed.ncbi.nlm.nih.gov/27872202/), [PMID: 15460900](https://pubmed.ncbi.nlm.nih.gov/15460900/) | [PMID: 11136714](https://pubmed.ncbi.nlm.nih.gov/11136714/), [PMID: 29665672](https://pubmed.ncbi.nlm.nih.gov/29665672/) |

Large germline 9p21 deletions that disrupt **both** proteins produce the **full melanoma + neural-tumor phenotype**, whereas **ARF-specific (exon 1β) lesions** particularly implicate p14ARF loss in the neural component—the pivotal human genetic insight of this syndrome ([PMID: 11136714](https://pubmed.ncbi.nlm.nih.gov/11136714/), [PMID: 12019208](https://pubmed.ncbi.nlm.nih.gov/12019208/)). Both branches require a somatic **second hit** (homozygous *CDKN2A/B* deletion) and cooperate with MAPK-pathway oncogenes (BRAF/RAS). The syndrome's combined skin-and-nervous-system targeting reflects the **shared neural-crest/neuroectodermal origin** of melanocytes, astrocytes, and Schwann cells.

---

## Evidence Base

| PMID | Role in this report | Evidence type |
|---|---|---|
| [9622062](https://pubmed.ncbi.nlm.nih.gov/9622062/) | 9p21 lesion disrupting p16/p19 segregates with MAS (MIM 155755) | Human kindred |
| [11136714](https://pubmed.ncbi.nlm.nih.gov/11136714/) | ARF-specific exon 1β germline deletion causes neural-tumor component | Human kindred |
| [35904890](https://pubmed.ncbi.nlm.nih.gov/35904890/) | CDKN2A exon 1B deletion → melanoma + neural tumors | Human kindred |
| [12019208](https://pubmed.ncbi.nlm.nih.gov/12019208/) | ARF haploinsufficiency; three-hit cooperation | Human kindred |
| [15937071](https://pubmed.ncbi.nlm.nih.gov/15937071/) | p14ARF exon 1β G16D in CMM+NST family | Human cohort |
| [28699883](https://pubmed.ncbi.nlm.nih.gov/28699883/) | Two-hit somatic homozygous CDKN2A/B deletion in MAS astrocytomas | Human case/tumor |
| [37585199](https://pubmed.ncbi.nlm.nih.gov/37585199/) | Prevalence & tumor spectrum; NF1-like phenotype | Biobank cohort |
| [21150883](https://pubmed.ncbi.nlm.nih.gov/21150883/) | Penetrance (pancreatic 58%, melanoma 39%); smoking HR 25.8 | Human cohort |
| [27872202](https://pubmed.ncbi.nlm.nih.gov/27872202/) | p16-mediated senescence barrier to melanoma | In vitro screen |
| [15460900](https://pubmed.ncbi.nlm.nih.gov/15460900/) | p16INK4a–Rb molecular mechanism | Review |
| [29665672](https://pubmed.ncbi.nlm.nih.gov/29665672/) | ARF–MDM2–p53 axis | Review |
| [21200141](https://pubmed.ncbi.nlm.nih.gov/21200141/) | p14ARF/CDKN2A deletion disables p53 in glioma | Review/in vitro |
| [30218143](https://pubmed.ncbi.nlm.nih.gov/30218143/) | Carrier melanoma phenotype (younger, multiple, thinner) | Human cohort |
| [32221274](https://pubmed.ncbi.nlm.nih.gov/32221274/) | Multiple primary melanomas; CDKN2A/MITF variants | Human cohort |
| [32482799](https://pubmed.ncbi.nlm.nih.gov/32482799/) | AD inheritance; p16-Leiden founder | Registry |
| [22636603](https://pubmed.ncbi.nlm.nih.gov/22636603/) | p16-Leiden nomenclature; FPC families | Human cohort |
| [35658523](https://pubmed.ncbi.nlm.nih.gov/35658523/) | Pancreatic surveillance yields resectable PDAC | Cohort |
| [36785917](https://pubmed.ncbi.nlm.nih.gov/36785917/) | Surveillance cost-effectiveness & survival gain | Modeling |
| [16462187](https://pubmed.ncbi.nlm.nih.gov/16462187/) | MC1R modifier; UV × genotype penetrance | Review |
| [31371819](https://pubmed.ncbi.nlm.nih.gov/31371819/) | Counseling reduces measured UV exposure | Prospective study |
| [23371019](https://pubmed.ncbi.nlm.nih.gov/23371019/) | UV dysregulates CDKN2A-het fibroblast transcriptome | In vitro |
| [12406321](https://pubmed.ncbi.nlm.nih.gov/12406321/) | Mouse: both Ink4a/Rb & Arf/p53 pathways in melanoma | Mouse |
| [42849920](https://pubmed.ncbi.nlm.nih.gov/42849920/) | Adjuvant therapy improves melanoma survival | Clinical cohort |
| [26183925](https://pubmed.ncbi.nlm.nih.gov/26183925/) | CDK4/6 inhibition rational in CDKN2A-null tumors | Preclinical |
| [38287743](https://pubmed.ncbi.nlm.nih.gov/38287743/) | Lifetime risk 52–84%; testing yield 10–40% | Review |
| [42630077](https://pubmed.ncbi.nlm.nih.gov/42630077/) | Homozygous CDKN2A/B deletion as WHO grade-4 criterion | Review |

---

## Limitations and Knowledge Gaps

1. **Rarity and ascertainment bias.** MAS is extremely rare; most data come from small kindreds and registries, giving wide confidence intervals (e.g., melanoma penetrance 95% CI 0–80%). Prevalence estimates span a >4-fold range (1:39,149–1:170,503).
2. **Incomplete ARF-specific genotype–phenotype resolution.** Whether isolated p14ARF loss is *sufficient* for the neural-tumor phenotype, or whether complete locus disruption / additional loci are required, remains partly unresolved ([PMID: 15937071](https://pubmed.ncbi.nlm.nih.gov/15937071/)).
3. **No syndrome-specific QoL, mortality, or natural-history data.** Outcomes are inferred from component-tumor literature rather than MAS-specific cohorts.
4. **Model gaps.** Mouse models capture the melanoma/MAPK/UV axis well but do not fully recapitulate the combined syndromic neural + cutaneous phenotype or human ARF exon-1β biology.
5. **No animal natural-disease analog** was identified.
6. **Modifier landscape** (beyond MC1R/MITF) and epigenetic contributions to the neural branch are underexplored.

---

## Proposed Follow-up Experiments / Actions

1. **ARF-isoform-specific mouse models** (conditional p19ARF-only deletion in neural-crest lineages) to test sufficiency of ARF loss for astrocytoma/schwannoma.
2. **Multi-omic profiling of MAS tumors** (WGS + methylation + single-cell) to map the somatic second-hit landscape and MAPK cooperation across the melanoma and neural branches.
3. **Prospective MAS-specific natural-history registry** capturing penetrance by tumor type, age, sex, and modifier genotype (MC1R, MITF), with QoL instruments.
4. **Clinical trials of CDK4/6 inhibitors** (± MAPK or IDH inhibitors) in CDKN2A-null MAS-associated tumors to validate the precision-oncology rationale ([PMID: 26183925](https://pubmed.ncbi.nlm.nih.gov/26183925/)).
5. **Optimize combined surveillance protocols** (skin + brain MRI + pancreatic MRI/EUS) and evaluate cost-effectiveness of adding neuroimaging for carriers with ARF-affecting variants.
6. **Behavioral-intervention trials** to sustain UV-reduction gains after genetic counseling ([PMID: 31371819](https://pubmed.ncbi.nlm.nih.gov/31371819/)).

---

*Report compiled from 13 confirmed findings across 5 investigation iterations and 64 reviewed papers. Evidence types span human kindreds/cohorts, biobank data, in vitro studies, mouse models, and reviews.*


## Artifacts

- [OpenScientist final report](Melanoma_And_Neural_System_Tumor_Syndrome-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Melanoma_And_Neural_System_Tumor_Syndrome-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 39 |
| Resolved | 39 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 5 |
| Quoted claims found in source | 5 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 39 |
| On topic | 22 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 25 |
| Resolved | 21 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 2 |
| Unverifiable | 2 |
| Terms whose name was checked | 18 |
| Terms named correctly | 9 |
| Terms named as a **different** term | 3 |
| Terms whose name is worth a second look | 6 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0007967` (2 mentions) - the report calls it "MONDO"; MONDO calls it **melanoma and neural system tumor syndrome**
- `HP:0012056` (2 mentions) - the report calls it "Cutaneous melanoma", "Earlier onset; carriers"; HP calls it **Cutaneous melanoma**
- `GO:0007050` (1 mention) - the report calls it "cell cycle arrest"; GO calls it **GO_0007050**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `HP:0100843` (obsolete Glioblastoma) (1 mention) - replaced by `HP:0012174`
- `GO:0007050` (GO_0007050) (1 mention) - replaced by `GO:0051726`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0100843` (1 mention) - the report calls it "Glioblastoma multiforme"; HP calls it **obsolete Glioblastoma**
- `HP:0002894` (1 mention) - the report calls it "Pancreatic adenocarcinoma"; HP calls it **Neoplasm of the pancreas**, and lists "Pancreatic cancer" among its other names
- `GO:0072332` (1 mention) - the report calls it "intrinsic apoptotic signaling by p53 class mediator"; GO calls it **intrinsic apoptotic signaling pathway by p53 class mediator**
- `GO:0000079` (1 mention) - the report calls it "regulation of CDK activity"; GO calls it **regulation of cyclin-dependent protein serine/threonine kinase activity**, and lists "regulation of CDK activity" among its other names
- `UBERON:0002097` (1 mention) - the report calls it "Primary:** skin"; UBERON calls it **skin of body**, and lists "entire skin" among its other names
- `UBERON:0001264` (1 mention) - the report calls it "Secondary:** pancreas"; UBERON calls it **pancreas**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `HP:0012056` - called "Cutaneous melanoma", "Earlier onset; carriers"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `HGF`.